Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 14 and younger than 65 years old~* Skin lesions with clinical suggestion of cutaneous leishmaniasis and positive leishmanin skin test(Montenegro test)or parasitological (direct observation of leishmania amastigotes, leishmania in vitro culture from aspirates, histopathological) and molecular(Polymerase Chain Reaction - PCR)samples.~* No use of oral potentially antileishmanial drugs, or topics throughout the term of the current injury.~* Absence of disseminated leishmaniasis.~* Absence of mucosal involvement.~* Agreement to participate in the study and signed the informed consent.~Exclusion Criteria:~* Diabetes mellitus, kidney diseases, liver or cardiac diseases, tuberculosis, malaria.~* Pregnancy~* lactating mothers~* Breast feeding~* Cutaneous lesion with bacterial infection for which antibiotics need to be prescribed~* More than six cutaneous lesions~* Previous history of cutaneous or mucosal leishmaniasis~* Use of drugs with potential pharmacological interactions with antimonials as anti-arrhythmic or tricycle anti-depressives~* Previous intolerance to azithromycin or other macrolides or N-methylglucamine~* Abusive alcohol ingestion according to the CAGE questionnaire

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A - N- methyl glucamine (Type: ACTIVE_COMPARATOR): Glucantime® , max day of 1,215 mg
- B - Azithromycin (Type: EXPERIMENTAL): Zithromax ® , one dose 500 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).